Searching for targets for the systemic therapy of mesothelioma

Autor: Rolf A. Stahel, Alessandra Curioni-Fontecedro, I. Schmitt-Opitz, Emanuela Felley-Bosco, Solange Peters, Walter Weder, Ulf Petrausch
Přispěvatelé: University of Zurich, Stahel, R A
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Oncology
Mesothelioma
medicine.medical_specialty
Pathology
Lung Neoplasms
medicine.medical_treatment
Pleural Neoplasms
2720 Hematology
610 Medicine & health
Disease
Pemetrexed
Systemic therapy
Targeted therapy
Phosphatidylinositol 3-Kinases
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Everolimus
Molecular Targeted Therapy
Protein Kinase Inhibitors
neoplasms
Phosphoinositide-3 Kinase Inhibitors
business.industry
TOR Serine-Threonine Kinases
Mesothelioma
Malignant
Combination chemotherapy
Hematology
Immunotherapy
respiratory system
medicine.disease
3. Good health
respiratory tract diseases
Radiation therapy
Focal Adhesion Protein-Tyrosine Kinases
10032 Clinic for Oncology and Hematology
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Cisplatin/administration & dosage
Everolimus/administration & dosage
Focal Adhesion Protein-Tyrosine Kinases/antagonists & inhibitors
Focal Adhesion Protein-Tyrosine Kinases/metabolism
Lung Neoplasms/drug therapy
Lung Neoplasms/metabolism
Mesothelioma/drug therapy
Mesothelioma/metabolism
Molecular Targeted Therapy/methods
Pemetrexed/administration & dosage
Phosphatidylinositol 3-Kinases/antagonists & inhibitors
Phosphatidylinositol 3-Kinases/metabolism
Pleural Neoplasms/drug therapy
Pleural Neoplasms/metabolism
Protein Kinase Inhibitors/administration & dosage
TOR Serine-Threonine Kinases/antagonists & inhibitors
TOR Serine-Threonine Kinases/metabolism
2730 Oncology
Cisplatin
business
medicine.drug
Zdroj: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo, vol. 26, no. 8, pp. 1649-1660
Popis: Malignant mesothelioma is an incurable disease associated with asbestos exposure arising in the pleural cavity and less frequently in the peritoneal cavity. Platinum-based combination chemotherapy with pemetrexed is the established standard of care. Multimodality approaches including surgery and radiotherapy are being investigated. Increasing knowledge about the molecular characteristics of mesothelioma had led to the identification of novel potential targets for systemic therapy. Current evidence suggests pathways activated in response to merlin deficiency, including Pi3K/mTOR and the focal adhesion kinase, as well as immunotherapeutic approaches to be most promising. This review elaborates on the rationale behind targeted approaches that have been and are undergoing exploration in mesothelioma and summarizes available clinical results and ongoing efforts to improve the systemic therapy of mesothelioma.
Databáze: OpenAIRE
Externí odkaz: